- Home
- AAMI vs VCEL Comparison
AAMI vs VCEL Comparison
Compare AAMI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | VCEL |
|---|---|---|
| Founded | 1980 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | AAMI | VCEL |
|---|---|---|
| Price | $72.30 | $32.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $58.00 | $57.75 |
| AVG Volume (30 Days) | 351.6K | ★ 570.7K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $32.73 | $19.40 |
| Revenue Next Year | $14.44 | $18.24 |
| P/E Ratio | $23.86 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $29.26 | $28.95 |
| 52 Week High | $76.13 | $45.97 |
Technical Indicators
Market Signals| Indicator | AAMI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 41.31 |
| Support Level | $46.04 | $31.45 |
| Resistance Level | $73.10 | $37.68 |
| Average True Range (ATR) | 2.49 | 1.37 |
| MACD | -0.12 | -0.16 |
| Stochastic Oscillator | 61.08 | 17.05 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.